CBSET at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

CBSET takes part in 1 session at ACT 2026 in San Antonio, and exhibits at Booth 507. Its program centres on how drugs can affect hearing and balance, and how to evaluate that risk to the ear as therapies move through clinical development.

Organization	ACT 2026 Attendance
CBSET Lexington, MA
cbset.com Contract research organizations (CROs) Non-profit translational research institute running GLP-compliant preclinical programs that move technically demanding therapies toward clinical testing.	Booth Exhibiting at Booth 507 Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm Session Wed Nov 18 9:00am–12:00pm Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14) Neurotoxicology · Translational safety · with Regeneron 9:00amIntroduction to Ototoxicity: Cochlear and Vestibular Toxicity (S14-1)Turner Scientific 9:25amThe Blood-Labyrinth-Barrier (BLB) and Biodistribution of a mAb into the Ear to Assess Ototoxicity (S14-2)Amgen 9:50amCase Study of DB-OTO: An AAV Gene Therapy for Auditory Neuropathy due to Otoferlin Variants (S14-3)Regeneron 10:45amPathology of Candidates Targeting Otic Conditions (S14-4)Greenfield Pathology Services 11:05amIntegrated Preclinical Approaches for Assessing Ototoxicity (S14-5)Cilcare 11:25amRegulatory Perspective: Guidance, Expectations, and Safety Pharmacology Assessment (S14-6)U.S. Food and Drug Administration

Organization

ACT 2026 Attendance

CBSET

Lexington, MA

cbset.com

Contract research organizations (CROs)

Non-profit translational research institute running GLP-compliant preclinical programs that move technically demanding therapies toward clinical testing.

Booth

Exhibiting at Booth 507

Mon, Nov 169:30am–6:30pmTue, Nov 178:00am–4:30pm

Session

Wed Nov 18
9:00am–12:00pm

Do You Hear What I Hear? Evaluating Otic and Vestibular Toxicity in Clinical Development (S14)

Neurotoxicology · Translational safety · with Regeneron

9:00amIntroduction to Ototoxicity: Cochlear and Vestibular Toxicity (S14-1)Turner Scientific
9:25amThe Blood-Labyrinth-Barrier (BLB) and Biodistribution of a mAb into the Ear to Assess Ototoxicity (S14-2)Amgen
9:50amCase Study of DB-OTO: An AAV Gene Therapy for Auditory Neuropathy due to Otoferlin Variants (S14-3)Regeneron
10:45amPathology of Candidates Targeting Otic Conditions (S14-4)Greenfield Pathology Services
11:05amIntegrated Preclinical Approaches for Assessing Ototoxicity (S14-5)Cilcare
11:25amRegulatory Perspective: Guidance, Expectations, and Safety Pharmacology Assessment (S14-6)U.S. Food and Drug Administration

Instantly find 20 buyers from CBSET

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction